Coronavirus Infections Clinical Trial
Official title:
Observational Program to Study the Preventive Efficacy of the BiVac Polio (Oral Polio Vaccine, Divalent, Live Attenuated of Types 1 and 3 ) Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19, Produced by FSBSI "Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products", on Volunteers Aged 18-65
Observational program, double-blind, placebo-controlled to study the preventive efficacy of the BiVac polio (Oral polio vaccine, divalent, live attenuated of types 1 and 3 vaccine against the incidence of acute respiratory infections, including COVID-19
To carry out a comparative assessment of the indices of humoral, cellular immunity and cytokine profile in patients with acute respiratory infections. Current Program Population: 1500 healthy male and female volunteers, aged of between 18 and 65 will be included in the program. All included volunteers will be divided into groups: Group 1 - 750 volunteers who will be vaccinated with BiVac polio vaccine; post-vaccination observation period of 12 months. Group 2 - 750 volunteers, placebo will be administered, post-vaccination observation period of 12 months. The probability of getting into one of the two groups for each volunteer will be 50%. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04553575 -
CoViD-19 Patient in Reims University Hospital in March to April 2020
|
||
Active, not recruiting |
NCT05033847 -
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
|
Phase 2 | |
Active, not recruiting |
NCT05548439 -
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a
|
Phase 1 | |
Completed |
NCT05046548 -
This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05726084 -
Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older
|
Phase 2/Phase 3 | |
Recruiting |
NCT05069129 -
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05054075 -
Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19
|
Phase 2 | |
Recruiting |
NCT05599516 -
Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial
|
Phase 3 | |
Completed |
NCT05047900 -
The Impact of SARS-CoV-2 Rapid Antigen Testing Kit Screening in Bangkok Community
|
N/A | |
Completed |
NCT04420286 -
Study of the Increase in ICU Beds Capacity During COVID-19 Pandemic in France
|
||
Completed |
NCT04424355 -
Magnetic Resonance Imaging to Detect Signs of Viral Pneumonia in Patients With Coronavirus Infection.
|
||
Terminated |
NCT04409873 -
Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)
|
Phase 2 | |
Enrolling by invitation |
NCT04327349 -
Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial
|
N/A | |
Completed |
NCT04321278 -
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)
|
Phase 3 | |
Recruiting |
NCT04327570 -
In-depth Immunological Investigation of COVID-19.
|
||
Completed |
NCT04326309 -
Audio Data Collection for Identification and Classification of Coughing
|
||
Recruiting |
NCT04322344 -
Escin in Patients With Covid-19 Infection
|
Phase 2/Phase 3 | |
Completed |
NCT04323592 -
Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome
|
||
Completed |
NCT04328129 -
Household Transmission Investigation Study for COVID-19 in Tropical Regions
|
N/A | |
Active, not recruiting |
NCT04305457 -
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19
|
Phase 2 |